FDA Approves Subcutaneous Induction of SKYRIZI for Moderate-to-Severe Crohn's
FROM THE WIRE · FINANCE.YAHOO.COM
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA new administration route for an AbbVie drug in a key indication may support sales.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA approved subcutaneous induction with an on-body injector for SKYRIZI.
- 02In the Phase 3 AFFIRM study, subcutaneous SKYRIZI beat placebo at week 12.
- 03The safety profile was generally consistent with the established SKYRIZI profile.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets